Compounds > thiazoles
Page last updated: 2024-08-21

thiazoles and capecitabine

thiazoles has been researched along with capecitabine in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Curtiss, FR1
Atzori, F; Cortes, J; Geese, WJ; Gradishar, WJ; Rybicki, A; Somlo, G; Specht, JM; Strauss, LC; Sy, O; Vahdat, LT1
Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY1

Trials

2 trial(s) available for thiazoles and capecitabine

ArticleYear
Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-01, Volume: 19, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Capecitabine; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrimidines; Thiazoles; Treatment Outcome

2013
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Dasatinib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Vascular Endothelial Growth Factor A

2014

Other Studies

1 other study(ies) available for thiazoles and capecitabine

ArticleYear
Pharmacy benefit spending on oral chemotherapy drugs.
    Journal of managed care pharmacy : JMCP, 2006, Volume: 12, Issue:7

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States

2006